What’s New in Antibiograms? Updating CLSI M39 Guidance with Current Trends-Reference-Cited by-同舟云学术

What’s New in Antibiograms? Updating CLSI M39 Guidance with Current Trends

Published:2022-10-19 Issue:10 Volume:60 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Simner Patricia J.¹^ORCID,Hindler Janet A.²,Bhowmick Tanaya³,Das Sanchita⁴^ORCID,Johnson J. Kristie⁵,Lubers Brian V.⁶,Redell Mark A.⁷,Stelling John⁸,Erdman Sharon M.⁹¹⁰

Affiliation:

1. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

2. Los Angeles County Department of Public Health, Los Angeles, California, USA

3. Rutgers Robert Wood Johnson Medical School, Department of Medicine, New Brunswick, New Jersey, USA

4. Department of Laboratory Medicine, National Institutes of Health, Clinical Center, Bethesda, Maryland, USA

5. Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA

6. Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA

7. Medical Affairs, Melinta Therapeutics, Morristown, New Jersey, USA

8. Microbiology Laboratory, Brigham and Women’s Hospital, Boston, Massachusetts, USA

9. Purdue University College of Pharmacy, West Lafayette, Indiana, USA

10. Eskenazi Health, Indianapolis, Indiana, USA

Abstract

A vast amount of antimicrobial susceptibility test (AST) data is generated from routine testing in diagnostic laboratories for the primary purpose of guiding clinicians in antimicrobial therapy decisions for their patients. However, there is additional value for these data when they are compiled at the local, regional, national, and global levels.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/jcm.02210-21

Reference23 articles.

1. Clinical and Laboratory Standards Institute. 2014. Analysis and presentation of cumulative antimicrobial susceptibility test data, 4th ed. Approved guideline. Clinical and Laboratory Standards Institute, Wayne, PA.

2. Clinical and Laboratory Standards Institute. 2022. Analysis and Presentation of cumulative antimicrobial susceptibility test data, 5th ed. Approved guideline. Clinical and Laboratory Standards Institute, Wayne, PA.

3. Clinical and Laboratory Standards Institute. 2022. Performance standards for antimicrobial susceptibility testing; 32nd informational supplement. CLSI M100-S32. Clinical and Laboratory Standards Institute, Wayne, PA.

4. Clinical and Laboratory Standards Institute. 2022. Performance standards for antimicrobial susceptibility testing; 32nd informational supplement (online version). http://em100.edaptivedocs.net/Login.aspx?_ga=2.16063088.755778026.1648416253-1304901391.1638386189&_gac=1.220515178.1647057379.CjwKCAiAg6yRBhBNEiwAeVyL0DX_L3o6I8oqmAifI6F5XlndKDWWDc9tXChSUHHpJZj4_OfEjm37AhoCVkMQAvD_BwE. Retrieved 7 April 2022.

5. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and antimicrobial susceptibility pattern of Klebsiella pneumoniae isolated from various clinical specimens at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia;BMC Infectious Diseases;2024-09-04

2. Deciphering the molecular mechanisms underlying anti-pathogenic potential of a polyherbal formulation Enteropan® against multidrug-resistant Pseudomonas aeruginosa;Drug Target Insights;2024-08-30

3. Silversol® (a Colloidal Nanosilver Formulation) Inhibits Growth of Antibiotic-Resistant Staphylococcus aureus by Disrupting Its Physiology in Multiple Ways;Pharmaceutics;2024-05-28

4. Silversol^®(a colloidal nanosilver formulation) inhibits growth of antibiotic-resistantStaphylococcus aureusby disrupting its physiology in multiple ways;2024-04-23

5. Retrospective analysis of pathogens for guided creation of an EMPIRIc antibiotic prEscribing pathway (EMPIRE);Journal of Burn Care & Research;2024-04-20